SGT2
protein
thekidney;SGT2 inhibitors blockthe
humansthatfacilitatesgucosereabsorptior
reabsorptionofglucoseinthekidney. increaseglucoseexcretion and lower bloodglucose uevels.SGLT2isa
low-affinity. hiqh-capacity alucosetransporteruocated intheproximattubuleinthekidneys;tisresponsiblefor
90%ofaucosereabsorotion.InhibitionofSGUT2leadstothedecreaseinbloodaucoseduetotheincreasein
renatglucoseexcretion.Themechanismofactionof thisnewclassofdruqs asooffersfurtheraucosecontroL
bvauowinaincreased insuuin sensitivityanduptakeofaucoseinthemuscleceus.decreasedauconeoaenesis
andimprovedfrst-phaseinsulin releasefromthebetacells.vaqinauyeastinfections and urinary tract
infectionsarethemostcommon side-effects.They alsocause significantoweringof HbAlc without increased
riskofhypoqtycaemia,reductionofbody weight and reductionofsystolicblood pressure.In addition,the
EMPA-REGtriatshowed thatempaqlifozin significantty reduced deaths among individuals with type2
diabetesandestablishedcardiovascuar disease whencompared with placebo.
@1MINENDOCRINE
